alzheimer's
A setback for the tau approach to Alzheimer's
From STAT's Andrew Joseph: In the effort to expand approaches to treating Alzheimer's beyond targeting amyloid, some companies have sought to target another protein thought to play a role in the disease — tau. But the approach faced a bit of a setback this week.
The Belgian biopharma UCB company presented data yesterday showing that its tau-targeting antibody called bepranemab successfully slowed tau accumulation versus placebo in a Phase 2 clinical trial. But the study, which enrolled more than 450 participants, did not meet its primary endpoint of slowing Alzheimer's progression, based on a commonly used metric known as Clinical Dementia Rating sum of boxes, CDR-SB.
UCB did some further slicing and dicing of its data, and found that patients who either had low levels of tau to begin with or who were not carriers of a particular genetic variant called APOE4 (or who fit both those groups) did see a slowing of disease progression on bepranemab. UCB's Matthew Barton, who presented the data at the Clinical Trials on Alzheimer's Disease conference in Madrid, said researchers were "encouraged" by the trial, and UCB said it is evaluating what steps to take next with bepranemab.
Expectations for the results were not particularly high. Last week, UCB said that Roche and its subsidiary Genentech, which had bought into bepranemab in 2020, had given back rights to the drug.
podcast
Lilly earnings surprise and a spooky ghost story
What would a Kamala Harris or Donald Trump presidency mean for health care policy? Why did Eli Lilly's Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast.
Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly's and Pfizer's surprise earnings reports. Then, they discuss what a Trump or Harris presidency could mean for health care and the biopharma industry, and what investors and biopharma executives think about either outcome.
Listen here.
No comments